NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC): Results of Operations and Financial Condition
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Wo
How this was made
The 30-second read
Why it matters
Traders can update expectations for FY2026 revenue based on the company’s stated guidance range, backlog/orders trajectory, and near-term milestones (ISO 13485 certification, StereoCED platform availability for research/IDE studies, and basivertebral nerve ablation partner discussions).
Market read
NMTC’s filing combines quantified financial performance (revenue, orders, backlog, gross margin) with multiple execution milestones that can drive sentiment and forward estimates.
What to watch
Guidance range ($9.2M to $10.5M) hinges on manufacturing completion and shipment timing; any supplier or logistics delays could swing outcomes even with strong gross margin performance.
NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%
Product revenue, gross profit and product gross margin increased year over year, while product orders exceeded quarterly revenue and backlog reached $1.7 million. The company remained loss-making, operating expenses increased, cash and working capital declined from September 30, 2025, and management said recognized revenue depends primarily on manufacturing completion and shipment timing.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenueGAAP | $ 1,973,105 | – | 16% |
| Cost of product revenueGAAP | 790,496 | – | – |
| Product gross profitGAAP | $ 1,182,609 | – | 29% |
| Product gross marginGAAP | 59.9% | – | 6.0 percentage point increase |
| License revenueGAAP | — | – | – |
| Selling, general and administrative expensesGAAP | $ 2,181,768 | – | – |
| Research and development expensesGAAP | $ 1,425,153 | – | – |
| Total operating expensesGAAP | $ 3,606,921 | – | – |
| Loss from operationsGAAP | $ (2,424,312 ) | – | – |
| Fair value change in warrant liabilityGAAP | 405,702 | – | – |
| Financing costsGAAP | — | – | – |
| Other incomeGAAP | 12,279 | – | – |
| Loss before income taxesGAAP | $ (2,006,331 ) | – | – |
| Provision for income taxesGAAP | — | – | – |
| Net lossGAAP | $ (2,006,331 ) | – | – |
| Net loss per share, basicGAAP | $ (0.23 ) | – | – |
| Net loss per share, dilutedGAAP | $ (0.28 ) | – | – |
| Number of shares used in basic per share calculationsGAAP | 8,661,624 | – | – |
| Number of shares used in diluted per share calculationsGAAP | 8,739,505 | – | – |
| Nine-month product revenueGAAP | $ 6,727,790 | – | – |
| Nine-month cost of product revenueGAAP | 2,987,089 | – | – |
| Nine-month product gross profitGAAP | 3,740,701 | – | – |
| Nine-month license revenueGAAP | — | – | – |
| Nine-month selling, general and administrative expensesGAAP | 5,986,594 | – | – |
| Nine-month research and development expensesGAAP | 4,282,923 | – | – |
| Nine-month total operating expensesGAAP | 10,269,517 | – | – |
| Nine-month loss from operationsGAAP | (6,528,816 ) | – | – |
| Nine-month fair value change in warrant liabilityGAAP | 620,171 | – | – |
| Nine-month financing costsGAAP | — | – | – |
| Nine-month other incomeGAAP | 82,402 | – | – |
| Nine-month loss before income taxesGAAP | (5,826,243 ) | – | – |
| Nine-month provision for income taxesGAAP | — | – | – |
| Nine-month net lossGAAP | $ (5,826,243 ) | – | – |
| Nine-month net loss per share, basicGAAP | $ (0.68 ) | – | – |
| Nine-month net loss per share, dilutedGAAP | $ (0.75 ) | – | – |
| Number of shares used in nine-month basic per share calculationsGAAP | 8,511,313 | – | – |
| Number of shares used in nine-month diluted per share calculationsGAAP | 8,621,075 | – | – |
Fiscal year 2026 outlook
- Revenue$9.2 million to $10.5 million
- NoteThe Company has received product orders of $11.2 million for fiscal year 2026.
- NoteNeuroOne expects its StereoCED™ platform to be available by the end of fiscal year 2026 for animal research and FDA IDE approved studies.
What drove it
- Product revenue increased primarily due to higher sales of OneRF® Products.
- Product gross margin expansion reflected a more favorable sales mix toward higher margin products.
- The Company received $2.7 million of new product orders to ship during the quarter, and backlog was $1.7 million as of June 30, 2026.
- The Company received ISO 13485:2016 Certification, which it said enables commercialization across different countries, subject to additional geographic requirements.
- Management cited the planned StereoCED™ launch, continued OneRF® Brain Ablation System growth, onboarding independent distributor representatives for the OneRF® Trigeminal Nerve Ablation System, a potential basivertebral nerve ablation access-tools partner, and international expansion planning.
Concerns
- Recognized revenue is expected to depend primarily on manufacturing completion and timing of shipments, and management is working with manufacturing partners to maximize shipments.
- Total operating expenses increased to $3.6 million from $2.8 million, driven by higher headcount, sales and marketing costs, professional fees and other operating costs, as well as the timing of product development activities.
- Net loss increased to $2.0 million from $1.5 million.
- Cash and cash equivalents declined to $2.0 million as of June 30, 2026 from $6.6 million as of September 30, 2025.
- The Company used its ATM program during the quarter and subsequent to quarter-end.
- The filing identifies risks relating to Nasdaq continued listing requirements, supply chain disruptions, labor shortages, capital requirements, reimbursement, regulatory requirements and clinical trial enrollment.
What to watch
- Product shipment execution against received fiscal year 2026 product orders of $11.2 million and the stated recognized revenue range of $9.2 million to $10.5 million.
- The amount of product orders that remain unshipped and contribute to backlog.
- Availability of the StereoCED™ platform for animal research and FDA IDE approved studies by the end of fiscal year 2026.
- Enrollment of the first patient in the brain ablation post-market registry by the end of September, with five centers currently participating.
- Progress in selecting a partner to develop access tools for the basivertebral nerve ablation system.
- Commercialization progress for the OneRF® Trigeminal Nerve Ablation System through a direct regional sales distribution model and independent distributor representatives.
Balance sheet and cash flow
- Cash and cash equivalents were $ 2,047,596 as of June 30, 2026, compared to $ 6,570,382 as of September 30, 2025.
- Accounts receivable were $ 1,098,965 as of June 30, 2026, compared to $ 1,264,805 as of September 30, 2025.
- Inventory, net was $ 2,290,254 as of June 30, 2026, compared to $ 2,226,805 as of September 30, 2025.
- Total current assets were 5,788,801 as of June 30, 2026, compared to 10,226,284 as of September 30, 2025.
- Total assets were $ 6,186,095 as of June 30, 2026, compared to $ 10,785,647 as of September 30, 2025.
- Total current liabilities were 2,041,427 as of June 30, 2026, compared to 2,303,083 as of September 30, 2025.
- Total liabilities were 2,418,552 as of June 30, 2026, compared to 3,713,125 as of September 30, 2025.
- Total stockholders’ equity was 3,767,543 as of June 30, 2026, compared to 7,072,522 as of September 30, 2025.
- The Company had working capital of $3.7 million as of June 30, 2026, compared to working capital of $7.9 million as of September 30, 2025.
- The Company had no debt outstanding as of June 30, 2026.
- During the third quarter of fiscal 2026, the Company raised $0.4 million through its at-the-market offering program.
- Through June 30, 2026, the Company raised gross proceeds of $8.4 million under the at-the-market (“ATM”) program.
- On July 13, 2026, the Company raised another $1.0 million through the issuance of 400,346 shares under the ATM program.
Analysis
NeuroOne reported product revenue of $2.0 million in fiscal Q3 2026, up 16% from $1.7 million in the year-ago quarter. Management attributed the increase primarily to higher sales of OneRF® Products. New product orders of $2.7 million exceeded recognized quarterly revenue, producing backlog of $1.7 million as of June 30, 2026. The company said it had received fiscal 2026 product orders of $11.2 million.
Margin performance improved materially. Product gross profit increased 29% to $1.2 million and product gross margin expanded to 59.9% from 53.9%. The company attributed the 6.0 percentage point expansion to a more favorable mix toward higher-margin products. This gross-profit improvement did not offset higher spending: total operating expenses increased to $3.6 million from $2.8 million, including SG&A of $2.2 million and R&D of $1.4 million.
The company remained unprofitable, reporting a net loss of $2.0 million, or ($0.23) per basic share and ($0.28) per diluted share, compared with a net loss of $1.5 million in the prior-year quarter. Liquidity declined, with cash and cash equivalents at $2.0 million and working capital at $3.7 million as of June 30, 2026, versus $6.6 million and $7.9 million, respectively, as of September 30, 2025. The company had no debt outstanding, but raised $0.4 million through its ATM program during the quarter and another $1.0 million after quarter-end.
The fiscal 2026 revenue outlook calls for recognized revenue of $9.2 million to $10.5 million. Management stated that the outcome depends primarily on manufacturing completion and shipment timing, with unshipped orders contributing to backlog. Operational milestones include ISO 13485:2016 certification, the expected availability of StereoCED™ for animal research and FDA IDE approved studies by fiscal year-end, and plans to enroll the first patient in the brain ablation post-market registry by the end of September. The principal near-term execution points are conversion of orders into shipments, preservation of the higher gross-margin mix, operating-expense control, and funding needs.
Management, verbatim
This quarter marked another period of revenue growth compared to 2025, with product revenue increasing 16% year-over-year to $2.0 million. Importantly, this growth is improving margins – product gross margins reached a record 59.9%, driven by a 29% increase in product gross profit to $1.2 million compared to the prior year period. Even more encouraging is that new product orders of $2.7 million during the quarter meaningfully outpaced revenue recognized during the quarter, growing our backlog to $1.7 million.
Dave Rosa, CEO of NeuroOne
Not in the filing
stated, not guessed- Prior quarterly release outlook, so comparison of actual results with prior guidance is unavailable.
- Non-GAAP revenue, gross profit, operating income, net income, EPS or reconciliations.
- Quarter-over-quarter comparisons for reported operating metrics.
- Operating cash flow.
- Free cash flow.
- Capital return activity, including share repurchases and dividends.
- Guidance for gross margin, operating expenses and tax rate.
- Segment revenue disclosure.
- A reported tax rate.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8-K (Item 2.02) includes NeuroOne’s Q3 FY2026 financial results and operational updates, filed with a press release exhibit.
Ticker impact
NeuroOne (NMTC) reported Q3 FY2026 results, with product revenue up 16% to $2.0M and gross margins rising to 59.9%.
Near-term bias positive if investors focus on margin expansion and backlog growth, but stock may remain volatile given small absolute revenue and execution risk on shipments and platform timelines.
The filing is a primary disclosure (8-K with Exhibit 99.1) including quantified revenue, orders/backlog, margin expansion, and multiple operational catalysts (ISO 13485, StereoCED availability timing, partner discussions). However, the company’s scale is small and revenue guidance depends on manufacturing completion and shipment timing, which can temper immediate re-rating.
Market effects
Adds incremental datapoints on commercialization readiness for neurosurgical device platforms (ISO 13485, platform availability for IDE/animal studies), relevant to small-cap medtech sentiment.
Limited direct regional read-through; primarily US small-cap medtech.
ISO 13485 certification supports potential international commercialization, but near-term impact is company-specific.
Counterpoint
Despite margin expansion, recognized revenue still lags product orders (orders exceed revenue), so near-term results may be more about timing than demand strength.
Key entities
- companyNeuroOne Medical Technologies Corporation
Nasdaq-listed medical technology company reporting Q3 FY2026 results and business updates in an SEC 8-K.
- product_platformStereoCED platform
Drug delivery system expected to be available by end of FY2026 for animal research and FDA IDE approved studies.
- productOneRF Brain Ablation System
Device referenced in a Journal of Neurosurgery publication and ongoing commercialization efforts.
- programBasivertebral nerve ablation access tools
Regulatory strategy complete, expected FDA 510(k) pathway, and partner discussions underway.
